SlideShare a Scribd company logo
 It is “Schedule under Part X-A of Drugs &
Cosmetics Rule 1945 describe the
information/data required –
Requirements and guidelines for permission to
import and/or manufacture of new drugs for
sale or undertake clinical trials
 Concurrent phase global clinical trials permitted,
 Phase I (first-in-human) study of New Drug
substance discovered outside the country, not
permitted( Repeat Phase I is permitted)
 Provides statutory support to Indian GCP
Guidelines
 Stipulates responsibilities of EC, Investigators and
Sponsor.
 Structure, contents and formats for CT protocols,
reports, EC approvals, ICF, SAE reporting are
incorporated .
Established Bulk drug
& formulation industry
Wide range of CRO’s
Vast Patient data
Diversity of
diseases
Compliant IT support
Cost Advantage
Highest number of
USFDA
approved plants
International Property
Rights
Advantages of conducting Clinical Trials
in India
 The amendment has brought in several good changes
- EC/CRO registration, GCP Compliance and other
related quality changes.
 Safeguard the safety of trial participants and to
improve the following much criticized inefficiencies:
 Misconduct, fraudulent cases of several clinical research
players including CROs, investigators, ECs, regulators and
sponsors.
 Ethical lapses in informed consent issues, protocol
violations, compensation issues among others.
 Compensation has to be paid irrespective of
whether or not the SAE is causally linked to IP.
 If this compensation is not provided, this may lead
to the company suspending/losing the license to
conduct CT in India on a case-by case basis. This is
acting as a deterrent for many pharma MNCs.
 DTAB meeting on May 16th, 2013- causality issue/
if the standard care is denied in case of placebo
trials/ failure of IP to act /streamline the timelines –
these recommendations are highly required to be
enacted
 These amendments have brought sudden change to
the CT regulations.
 Many of these amendments were long overdue and
were very much required however without too many
lacunas.
 These changes should have been done in
consultation with the stakeholders (Public, Sponsors,
CROs, Academia, Ethics Committees, Regulators and
Ministry) to avoid the anguish that the CT industry is
undergoing currently.
SchY.ppt

More Related Content

Similar to SchY.ppt

Presentation: Inaugural Industry Forum on Good Manufacturing Practice
Presentation: Inaugural Industry Forum on Good Manufacturing PracticePresentation: Inaugural Industry Forum on Good Manufacturing Practice
Presentation: Inaugural Industry Forum on Good Manufacturing Practice
TGA Australia
 
Common Technical Document
Common Technical DocumentCommon Technical Document
Common Technical Document
Dr Sukanta sen
 
Regulatory Affairs as a Career Path
Regulatory Affairs as a Career PathRegulatory Affairs as a Career Path
Regulatory Affairs as a Career Path
Plamena Entcheva-Dimitrov, PhD, RAC
 
Pharma Policy 2017 - Read it in MedicinMan September 2017 Issue
Pharma Policy 2017 - Read it in MedicinMan September 2017 IssuePharma Policy 2017 - Read it in MedicinMan September 2017 Issue
Pharma Policy 2017 - Read it in MedicinMan September 2017 Issue
Anup Soans
 
Clinical trials legal issues
Clinical trials   legal issuesClinical trials   legal issues
Clinical trials legal issues
Upendra Rangavajjula
 
BC.MRCT.TS story
BC.MRCT.TS storyBC.MRCT.TS story
BC.MRCT.TS story
Tamra Sami
 
Subject Matter Patent Eligibility, 2015, Rodney Sparks
Subject Matter Patent Eligibility, 2015, Rodney SparksSubject Matter Patent Eligibility, 2015, Rodney Sparks
Subject Matter Patent Eligibility, 2015, Rodney Sparks
Rodney Sparks
 
A New Regulatory Model for India
A New Regulatory Model for IndiaA New Regulatory Model for India
A New Regulatory Model for India
Heena Thakkar
 
Timeline Summary to keep the record straight
Timeline Summary to keep the record straightTimeline Summary to keep the record straight
Timeline Summary to keep the record straight
Obaid Ali / Roohi B. Obaid
 
Devices Sponsor Information Day: 0 - Developments in medical device regulation
Devices Sponsor Information Day: 0 - Developments in medical device regulationDevices Sponsor Information Day: 0 - Developments in medical device regulation
Devices Sponsor Information Day: 0 - Developments in medical device regulation
TGA Australia
 
When product approval data can be manipulated, why exclusivity and data prote...
When product approval data can be manipulated, why exclusivity and data prote...When product approval data can be manipulated, why exclusivity and data prote...
When product approval data can be manipulated, why exclusivity and data prote...
VIJAY SARDANA
 
Drug Regulatory Affairs
Drug Regulatory AffairsDrug Regulatory Affairs
Drug Regulatory Affairs
Namdeo Shinde
 
OSMA: Orthopedic Industry's Top Regulatory Challenges and Opportunities
OSMA: Orthopedic Industry's Top Regulatory Challenges and OpportunitiesOSMA: Orthopedic Industry's Top Regulatory Challenges and Opportunities
OSMA: Orthopedic Industry's Top Regulatory Challenges and Opportunities
April Bright
 
Key current and future regulatory challenges in the Medical Device and/or IVD...
Key current and future regulatory challenges in the Medical Device and/or IVD...Key current and future regulatory challenges in the Medical Device and/or IVD...
Key current and future regulatory challenges in the Medical Device and/or IVD...
Diane Hatziioanou
 
Current regulatory challenges in indian pharmaceutical industry
Current regulatory challenges in indian pharmaceutical industryCurrent regulatory challenges in indian pharmaceutical industry
Current regulatory challenges in indian pharmaceutical industry
Vikas Rathee
 
Dr_Prabhat_Roy_Kumar_CT_regulatory_challnages_in_India__19Nov14__revised.ppt
Dr_Prabhat_Roy_Kumar_CT_regulatory_challnages_in_India__19Nov14__revised.pptDr_Prabhat_Roy_Kumar_CT_regulatory_challnages_in_India__19Nov14__revised.ppt
Dr_Prabhat_Roy_Kumar_CT_regulatory_challnages_in_India__19Nov14__revised.ppt
RRahulMehrotrra1
 
Pharma Uptoday Monthly Magazine - Volume 18; Issue: Sep 2015
Pharma Uptoday Monthly Magazine - Volume 18; Issue: Sep 2015Pharma Uptoday Monthly Magazine - Volume 18; Issue: Sep 2015
Pharma Uptoday Monthly Magazine - Volume 18; Issue: Sep 2015
Sathish Vemula
 
Overcoming Regulatory, Clinical and Quality Challenges in Developing Combinat...
Overcoming Regulatory, Clinical and Quality Challenges in Developing Combinat...Overcoming Regulatory, Clinical and Quality Challenges in Developing Combinat...
Overcoming Regulatory, Clinical and Quality Challenges in Developing Combinat...
Michael Swit
 
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...
TGA Australia
 
presentation-ema-experience-mdr-implementation_en.pdf
presentation-ema-experience-mdr-implementation_en.pdfpresentation-ema-experience-mdr-implementation_en.pdf
presentation-ema-experience-mdr-implementation_en.pdf
Balaji Kuzhandhaivelu
 

Similar to SchY.ppt (20)

Presentation: Inaugural Industry Forum on Good Manufacturing Practice
Presentation: Inaugural Industry Forum on Good Manufacturing PracticePresentation: Inaugural Industry Forum on Good Manufacturing Practice
Presentation: Inaugural Industry Forum on Good Manufacturing Practice
 
Common Technical Document
Common Technical DocumentCommon Technical Document
Common Technical Document
 
Regulatory Affairs as a Career Path
Regulatory Affairs as a Career PathRegulatory Affairs as a Career Path
Regulatory Affairs as a Career Path
 
Pharma Policy 2017 - Read it in MedicinMan September 2017 Issue
Pharma Policy 2017 - Read it in MedicinMan September 2017 IssuePharma Policy 2017 - Read it in MedicinMan September 2017 Issue
Pharma Policy 2017 - Read it in MedicinMan September 2017 Issue
 
Clinical trials legal issues
Clinical trials   legal issuesClinical trials   legal issues
Clinical trials legal issues
 
BC.MRCT.TS story
BC.MRCT.TS storyBC.MRCT.TS story
BC.MRCT.TS story
 
Subject Matter Patent Eligibility, 2015, Rodney Sparks
Subject Matter Patent Eligibility, 2015, Rodney SparksSubject Matter Patent Eligibility, 2015, Rodney Sparks
Subject Matter Patent Eligibility, 2015, Rodney Sparks
 
A New Regulatory Model for India
A New Regulatory Model for IndiaA New Regulatory Model for India
A New Regulatory Model for India
 
Timeline Summary to keep the record straight
Timeline Summary to keep the record straightTimeline Summary to keep the record straight
Timeline Summary to keep the record straight
 
Devices Sponsor Information Day: 0 - Developments in medical device regulation
Devices Sponsor Information Day: 0 - Developments in medical device regulationDevices Sponsor Information Day: 0 - Developments in medical device regulation
Devices Sponsor Information Day: 0 - Developments in medical device regulation
 
When product approval data can be manipulated, why exclusivity and data prote...
When product approval data can be manipulated, why exclusivity and data prote...When product approval data can be manipulated, why exclusivity and data prote...
When product approval data can be manipulated, why exclusivity and data prote...
 
Drug Regulatory Affairs
Drug Regulatory AffairsDrug Regulatory Affairs
Drug Regulatory Affairs
 
OSMA: Orthopedic Industry's Top Regulatory Challenges and Opportunities
OSMA: Orthopedic Industry's Top Regulatory Challenges and OpportunitiesOSMA: Orthopedic Industry's Top Regulatory Challenges and Opportunities
OSMA: Orthopedic Industry's Top Regulatory Challenges and Opportunities
 
Key current and future regulatory challenges in the Medical Device and/or IVD...
Key current and future regulatory challenges in the Medical Device and/or IVD...Key current and future regulatory challenges in the Medical Device and/or IVD...
Key current and future regulatory challenges in the Medical Device and/or IVD...
 
Current regulatory challenges in indian pharmaceutical industry
Current regulatory challenges in indian pharmaceutical industryCurrent regulatory challenges in indian pharmaceutical industry
Current regulatory challenges in indian pharmaceutical industry
 
Dr_Prabhat_Roy_Kumar_CT_regulatory_challnages_in_India__19Nov14__revised.ppt
Dr_Prabhat_Roy_Kumar_CT_regulatory_challnages_in_India__19Nov14__revised.pptDr_Prabhat_Roy_Kumar_CT_regulatory_challnages_in_India__19Nov14__revised.ppt
Dr_Prabhat_Roy_Kumar_CT_regulatory_challnages_in_India__19Nov14__revised.ppt
 
Pharma Uptoday Monthly Magazine - Volume 18; Issue: Sep 2015
Pharma Uptoday Monthly Magazine - Volume 18; Issue: Sep 2015Pharma Uptoday Monthly Magazine - Volume 18; Issue: Sep 2015
Pharma Uptoday Monthly Magazine - Volume 18; Issue: Sep 2015
 
Overcoming Regulatory, Clinical and Quality Challenges in Developing Combinat...
Overcoming Regulatory, Clinical and Quality Challenges in Developing Combinat...Overcoming Regulatory, Clinical and Quality Challenges in Developing Combinat...
Overcoming Regulatory, Clinical and Quality Challenges in Developing Combinat...
 
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...
 
presentation-ema-experience-mdr-implementation_en.pdf
presentation-ema-experience-mdr-implementation_en.pdfpresentation-ema-experience-mdr-implementation_en.pdf
presentation-ema-experience-mdr-implementation_en.pdf
 

More from Priyanka Saroj

angina ppt.ppt
angina ppt.pptangina ppt.ppt
angina ppt.ppt
Priyanka Saroj
 
02 Drug Targeting and validation.ppt
02 Drug Targeting and validation.ppt02 Drug Targeting and validation.ppt
02 Drug Targeting and validation.ppt
Priyanka Saroj
 
GABA.pptx
GABA.pptxGABA.pptx
GABA.pptx
Priyanka Saroj
 
BIOASSAYS.pptx
BIOASSAYS.pptxBIOASSAYS.pptx
BIOASSAYS.pptx
Priyanka Saroj
 
Adrenergic system.pptx
Adrenergic system.pptxAdrenergic system.pptx
Adrenergic system.pptx
Priyanka Saroj
 
Drug development1.ppt
Drug development1.pptDrug development1.ppt
Drug development1.ppt
Priyanka Saroj
 
SIGNAL TRANSDUCTION (1).pptx
SIGNAL TRANSDUCTION (1).pptxSIGNAL TRANSDUCTION (1).pptx
SIGNAL TRANSDUCTION (1).pptx
Priyanka Saroj
 

More from Priyanka Saroj (7)

angina ppt.ppt
angina ppt.pptangina ppt.ppt
angina ppt.ppt
 
02 Drug Targeting and validation.ppt
02 Drug Targeting and validation.ppt02 Drug Targeting and validation.ppt
02 Drug Targeting and validation.ppt
 
GABA.pptx
GABA.pptxGABA.pptx
GABA.pptx
 
BIOASSAYS.pptx
BIOASSAYS.pptxBIOASSAYS.pptx
BIOASSAYS.pptx
 
Adrenergic system.pptx
Adrenergic system.pptxAdrenergic system.pptx
Adrenergic system.pptx
 
Drug development1.ppt
Drug development1.pptDrug development1.ppt
Drug development1.ppt
 
SIGNAL TRANSDUCTION (1).pptx
SIGNAL TRANSDUCTION (1).pptxSIGNAL TRANSDUCTION (1).pptx
SIGNAL TRANSDUCTION (1).pptx
 

Recently uploaded

Sciences of Europe journal No 142 (2024)
Sciences of Europe journal No 142 (2024)Sciences of Europe journal No 142 (2024)
Sciences of Europe journal No 142 (2024)
Sciences of Europe
 
GBSN - Biochemistry (Unit 6) Chemistry of Proteins
GBSN - Biochemistry (Unit 6) Chemistry of ProteinsGBSN - Biochemistry (Unit 6) Chemistry of Proteins
GBSN - Biochemistry (Unit 6) Chemistry of Proteins
Areesha Ahmad
 
molar-distalization in orthodontics-seminar.pptx
molar-distalization in orthodontics-seminar.pptxmolar-distalization in orthodontics-seminar.pptx
molar-distalization in orthodontics-seminar.pptx
Anagha Prasad
 
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...
THEMATIC  APPERCEPTION  TEST(TAT) cognitive abilities, creativity, and critic...THEMATIC  APPERCEPTION  TEST(TAT) cognitive abilities, creativity, and critic...
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...
Abdul Wali Khan University Mardan,kP,Pakistan
 
8.Isolation of pure cultures and preservation of cultures.pdf
8.Isolation of pure cultures and preservation of cultures.pdf8.Isolation of pure cultures and preservation of cultures.pdf
8.Isolation of pure cultures and preservation of cultures.pdf
by6843629
 
Thornton ESPP slides UK WW Network 4_6_24.pdf
Thornton ESPP slides UK WW Network 4_6_24.pdfThornton ESPP slides UK WW Network 4_6_24.pdf
Thornton ESPP slides UK WW Network 4_6_24.pdf
European Sustainable Phosphorus Platform
 
Oedema_types_causes_pathophysiology.pptx
Oedema_types_causes_pathophysiology.pptxOedema_types_causes_pathophysiology.pptx
Oedema_types_causes_pathophysiology.pptx
muralinath2
 
waterlessdyeingtechnolgyusing carbon dioxide chemicalspdf
waterlessdyeingtechnolgyusing carbon dioxide chemicalspdfwaterlessdyeingtechnolgyusing carbon dioxide chemicalspdf
waterlessdyeingtechnolgyusing carbon dioxide chemicalspdf
LengamoLAppostilic
 
Phenomics assisted breeding in crop improvement
Phenomics assisted breeding in crop improvementPhenomics assisted breeding in crop improvement
Phenomics assisted breeding in crop improvement
IshaGoswami9
 
Basics of crystallography, crystal systems, classes and different forms
Basics of crystallography, crystal systems, classes and different formsBasics of crystallography, crystal systems, classes and different forms
Basics of crystallography, crystal systems, classes and different forms
MaheshaNanjegowda
 
SAR of Medicinal Chemistry 1st by dk.pdf
SAR of Medicinal Chemistry 1st by dk.pdfSAR of Medicinal Chemistry 1st by dk.pdf
SAR of Medicinal Chemistry 1st by dk.pdf
KrushnaDarade1
 
Describing and Interpreting an Immersive Learning Case with the Immersion Cub...
Describing and Interpreting an Immersive Learning Case with the Immersion Cub...Describing and Interpreting an Immersive Learning Case with the Immersion Cub...
Describing and Interpreting an Immersive Learning Case with the Immersion Cub...
Leonel Morgado
 
The cost of acquiring information by natural selection
The cost of acquiring information by natural selectionThe cost of acquiring information by natural selection
The cost of acquiring information by natural selection
Carl Bergstrom
 
Direct Seeded Rice - Climate Smart Agriculture
Direct Seeded Rice - Climate Smart AgricultureDirect Seeded Rice - Climate Smart Agriculture
Direct Seeded Rice - Climate Smart Agriculture
International Food Policy Research Institute- South Asia Office
 
在线办理(salfor毕业证书)索尔福德大学毕业证毕业完成信一模一样
在线办理(salfor毕业证书)索尔福德大学毕业证毕业完成信一模一样在线办理(salfor毕业证书)索尔福德大学毕业证毕业完成信一模一样
在线办理(salfor毕业证书)索尔福德大学毕业证毕业完成信一模一样
vluwdy49
 
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốtmô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
HongcNguyn6
 
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...
University of Maribor
 
Equivariant neural networks and representation theory
Equivariant neural networks and representation theoryEquivariant neural networks and representation theory
Equivariant neural networks and representation theory
Daniel Tubbenhauer
 
Shallowest Oil Discovery of Turkiye.pptx
Shallowest Oil Discovery of Turkiye.pptxShallowest Oil Discovery of Turkiye.pptx
Shallowest Oil Discovery of Turkiye.pptx
Gokturk Mehmet Dilci
 
20240520 Planning a Circuit Simulator in JavaScript.pptx
20240520 Planning a Circuit Simulator in JavaScript.pptx20240520 Planning a Circuit Simulator in JavaScript.pptx
20240520 Planning a Circuit Simulator in JavaScript.pptx
Sharon Liu
 

Recently uploaded (20)

Sciences of Europe journal No 142 (2024)
Sciences of Europe journal No 142 (2024)Sciences of Europe journal No 142 (2024)
Sciences of Europe journal No 142 (2024)
 
GBSN - Biochemistry (Unit 6) Chemistry of Proteins
GBSN - Biochemistry (Unit 6) Chemistry of ProteinsGBSN - Biochemistry (Unit 6) Chemistry of Proteins
GBSN - Biochemistry (Unit 6) Chemistry of Proteins
 
molar-distalization in orthodontics-seminar.pptx
molar-distalization in orthodontics-seminar.pptxmolar-distalization in orthodontics-seminar.pptx
molar-distalization in orthodontics-seminar.pptx
 
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...
THEMATIC  APPERCEPTION  TEST(TAT) cognitive abilities, creativity, and critic...THEMATIC  APPERCEPTION  TEST(TAT) cognitive abilities, creativity, and critic...
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...
 
8.Isolation of pure cultures and preservation of cultures.pdf
8.Isolation of pure cultures and preservation of cultures.pdf8.Isolation of pure cultures and preservation of cultures.pdf
8.Isolation of pure cultures and preservation of cultures.pdf
 
Thornton ESPP slides UK WW Network 4_6_24.pdf
Thornton ESPP slides UK WW Network 4_6_24.pdfThornton ESPP slides UK WW Network 4_6_24.pdf
Thornton ESPP slides UK WW Network 4_6_24.pdf
 
Oedema_types_causes_pathophysiology.pptx
Oedema_types_causes_pathophysiology.pptxOedema_types_causes_pathophysiology.pptx
Oedema_types_causes_pathophysiology.pptx
 
waterlessdyeingtechnolgyusing carbon dioxide chemicalspdf
waterlessdyeingtechnolgyusing carbon dioxide chemicalspdfwaterlessdyeingtechnolgyusing carbon dioxide chemicalspdf
waterlessdyeingtechnolgyusing carbon dioxide chemicalspdf
 
Phenomics assisted breeding in crop improvement
Phenomics assisted breeding in crop improvementPhenomics assisted breeding in crop improvement
Phenomics assisted breeding in crop improvement
 
Basics of crystallography, crystal systems, classes and different forms
Basics of crystallography, crystal systems, classes and different formsBasics of crystallography, crystal systems, classes and different forms
Basics of crystallography, crystal systems, classes and different forms
 
SAR of Medicinal Chemistry 1st by dk.pdf
SAR of Medicinal Chemistry 1st by dk.pdfSAR of Medicinal Chemistry 1st by dk.pdf
SAR of Medicinal Chemistry 1st by dk.pdf
 
Describing and Interpreting an Immersive Learning Case with the Immersion Cub...
Describing and Interpreting an Immersive Learning Case with the Immersion Cub...Describing and Interpreting an Immersive Learning Case with the Immersion Cub...
Describing and Interpreting an Immersive Learning Case with the Immersion Cub...
 
The cost of acquiring information by natural selection
The cost of acquiring information by natural selectionThe cost of acquiring information by natural selection
The cost of acquiring information by natural selection
 
Direct Seeded Rice - Climate Smart Agriculture
Direct Seeded Rice - Climate Smart AgricultureDirect Seeded Rice - Climate Smart Agriculture
Direct Seeded Rice - Climate Smart Agriculture
 
在线办理(salfor毕业证书)索尔福德大学毕业证毕业完成信一模一样
在线办理(salfor毕业证书)索尔福德大学毕业证毕业完成信一模一样在线办理(salfor毕业证书)索尔福德大学毕业证毕业完成信一模一样
在线办理(salfor毕业证书)索尔福德大学毕业证毕业完成信一模一样
 
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốtmô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
 
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...
 
Equivariant neural networks and representation theory
Equivariant neural networks and representation theoryEquivariant neural networks and representation theory
Equivariant neural networks and representation theory
 
Shallowest Oil Discovery of Turkiye.pptx
Shallowest Oil Discovery of Turkiye.pptxShallowest Oil Discovery of Turkiye.pptx
Shallowest Oil Discovery of Turkiye.pptx
 
20240520 Planning a Circuit Simulator in JavaScript.pptx
20240520 Planning a Circuit Simulator in JavaScript.pptx20240520 Planning a Circuit Simulator in JavaScript.pptx
20240520 Planning a Circuit Simulator in JavaScript.pptx
 

SchY.ppt

  • 1.  It is “Schedule under Part X-A of Drugs & Cosmetics Rule 1945 describe the information/data required – Requirements and guidelines for permission to import and/or manufacture of new drugs for sale or undertake clinical trials
  • 2.  Concurrent phase global clinical trials permitted,  Phase I (first-in-human) study of New Drug substance discovered outside the country, not permitted( Repeat Phase I is permitted)  Provides statutory support to Indian GCP Guidelines  Stipulates responsibilities of EC, Investigators and Sponsor.  Structure, contents and formats for CT protocols, reports, EC approvals, ICF, SAE reporting are incorporated .
  • 3.
  • 4. Established Bulk drug & formulation industry Wide range of CRO’s Vast Patient data Diversity of diseases Compliant IT support Cost Advantage Highest number of USFDA approved plants International Property Rights Advantages of conducting Clinical Trials in India
  • 5.  The amendment has brought in several good changes - EC/CRO registration, GCP Compliance and other related quality changes.  Safeguard the safety of trial participants and to improve the following much criticized inefficiencies:  Misconduct, fraudulent cases of several clinical research players including CROs, investigators, ECs, regulators and sponsors.  Ethical lapses in informed consent issues, protocol violations, compensation issues among others.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.  Compensation has to be paid irrespective of whether or not the SAE is causally linked to IP.  If this compensation is not provided, this may lead to the company suspending/losing the license to conduct CT in India on a case-by case basis. This is acting as a deterrent for many pharma MNCs.  DTAB meeting on May 16th, 2013- causality issue/ if the standard care is denied in case of placebo trials/ failure of IP to act /streamline the timelines – these recommendations are highly required to be enacted
  • 27.
  • 28.
  • 29.  These amendments have brought sudden change to the CT regulations.  Many of these amendments were long overdue and were very much required however without too many lacunas.  These changes should have been done in consultation with the stakeholders (Public, Sponsors, CROs, Academia, Ethics Committees, Regulators and Ministry) to avoid the anguish that the CT industry is undergoing currently.

Editor's Notes

  1. Post-marketing only
  2. Post-marketing only